Adicet Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Adicet Bio, Inc. (ACET) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.29% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-05
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-06-30 was 4.29%, a 4.63% increase year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-03-31 was 4.06%, a 8.35% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-09-30 was 4.00%, a 0.25% increase year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.10%, a 8.89% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.43%, a 1.99% decline from fiscal 2024.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.52%, a 7.00% decline from fiscal 2023.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.86%, a 15.17% increase from fiscal 2022.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.22%, a 201.43% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.29% 10-Q · filed 2026-08-05 | 4.29% 10-Q · filed 2026-08-05 | ||
| 2026-03-31 | 4.06% 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 4.43% 10-K · filed 2026-03-12 | |||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-05 | 4.43% 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 4.10% 10-Q · filed 2026-08-05 | 4.40% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 4.43% 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 4.52% 10-K · filed 2026-03-12 | |||
| 2024-09-30 | 3.99% 10-Q · filed 2025-11-05 | 4.52% 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-07 | 4.50% 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 4.27% 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 4.86% 10-K · filed 2025-03-06 | |||
| 2023-09-30 | 4.60% 10-Q · filed 2024-11-06 | 4.60% 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 4.10% 10-Q · filed 2024-08-13 | 4.20% 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | 4.22% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 4.22% 10-K · filed 2024-03-19 | |||
| 2022-09-30 | 4.00% 10-Q · filed 2023-11-08 | 4.00% 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-09 | 3.00% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 2.40% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 1.40% 10-K · filed 2023-03-15 | |||
| 2021-09-30 | 1.20% 10-Q · filed 2021-11-10 | 1.20% 10-Q · filed 2021-11-10 | ||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-10 | 1.10% 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | 0.90% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 1.70% 10-K · filed 2022-03-15 | |||
| 2020-09-30 | 0.40% 10-Q · filed 2021-11-10 | 1.70% 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | 0.50% 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |